• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2015

  • ID: 1196697
  • January 2015
  • Region: Global
  • Bioseeker

Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, there is plenty of room for more competition.

There are today 341 companies plus partners developing 590 PKI drugs in 2360 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 443 drugs. Protein Kinase Inhibitors In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 266 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 258 out of the 263 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed READ MORE >

Note: Product cover images may vary from those shown



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Amgen Inc. Bayer AG Bio-Rad Laboratories, Inc. Beckman Coulter, Inc. Novartis AG Baxter International Inc.